Aviex Technologies, LLC was founded
to develop a novel, rapid response vaccine platform for infectious diseases.

Product Pipeline

AVIEX #1: CLOSTRIDIUM difficile (C. difficile) ORAL VACCINE

Aviex has selected the bacterium C. difficile as the initial vaccine target for its enhanced YS1646 vaccine platform technology. Background on C. difficile is provided below:

AVIEX-#2: SCHISTOSOMA mansoni (S. mansoni) ORAL VACCINE

Like C. difficile, this is a life threatening disease of the gut caused by a flat worm parasite. It is only exceeded by Malaria as a parasitic pathogen affecting humans. Although some anti-parasiticals are effective, resistance is increasing, thus vaccines are of immense importance. Unfortunately there is no commercial vaccine for any human schistosome. This is a disease, found in less developed countries, that sickens over 200,000 individuals, and kills in excess of 20,000 people per year.

  • AVIEX-#3: CRYPTOSPORIRIDIUM parvum (C. parvum) ORAL VACCINE

    This protozoan parasite,of global importance, can affect both humans and animals, and may cause fatal diarrhea. This disease is also classified by the CDC as a Bioterrorism Category B threat, because of the potential for use as a biologic weapon. 0